These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20726858)

  • 21. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
    Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
    Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation.
    Qin L; Tamasi J; Raggatt L; Li X; Feyen JH; Lee DC; Dicicco-Bloom E; Partridge NC
    J Biol Chem; 2005 Feb; 280(5):3974-81. PubMed ID: 15509566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
    Oshima H; Popivanova BK; Oguma K; Kong D; Ishikawa TO; Oshima M
    Cancer Sci; 2011 Apr; 102(4):713-9. PubMed ID: 21205091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphiregulin attenuates bleomycin-induced pneumopathy in mice.
    Fukumoto J; Harada C; Kawaguchi T; Suetsugu S; Maeyama T; Inoshima I; Hamada N; Kuwano K; Nakanishi Y
    Am J Physiol Lung Cell Mol Physiol; 2010 Feb; 298(2):L131-8. PubMed ID: 19915156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
    Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
    Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
    Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
    Martínez-Palacián A; Del Castillo G; Herrera B; Fernández M; Roncero C; Fabregat I; Sánchez A
    Cell Signal; 2012 Feb; 24(2):505-513. PubMed ID: 22001397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
    Chai X; Chu H; Yang X; Meng Y; Shi P; Gou S
    Sci Rep; 2015 Sep; 5():14404. PubMed ID: 26391180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
    Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
    Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
    Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
    Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
    Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
    Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
    Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
    Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
    Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.